Introduction: Colorectal Cancer

  • M. A. Hayat
Part of the Methods of Cancer Diagnosis, Therapy, and Prognosis book series (HAYAT, volume 4)

An immense burden is associated with cancer worldwide. This is especially evident among citizens of developing countries. A case in point is that approximately 500,000 women develop cervical cancer each year worldwide, resulting in 250,000 deaths, and 80% of this cancer occurs in developing countries. Many factors, including socio-economic status, cultural perception of malignant conditions, the cost of anticancer chemotherapy, and the paucity of radiation and hospital facilities, (i.e., cancer screening), insufficient transmission of oncology-related information, and, most importantly, inadequate diet, are responsible for the suffering among those in the developing world. Although efforts are being undertaken by private organizations and institutions for reducing the burden of cancer in developing countries, it is evident that governments of developed countries could do much more to address the problem.

Because significant improvements in the prevention and treatment of cardiovascular diseases have occurred, cancer will become the leading cause of death in many parts of the world. In addition, cancer will remain a major health problem, as population aging continues in many countries and elderly persons are more susceptible to this form of malignancy. Approximately, 60% of cancer incidence and 70% of cancer mortality occur among older adults (65 years and older). Unfortunately, it should be noted that cancer care for frail older adults has been mostly unrepresented in clinical trials.

Keywords

Migration Toxicity Adenoma Neuropathy Oncol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Avallone, A., Delrio, P., Guida, C., Tatangelo, F., Petrillo, A., Lastoria, S., Parisi, V., Comella, G., Budillon, A., and Comella, P. 2007. High rate of TRG1-2 and prolonged RFS with OXA/ TOM and FU/LFA during preoperative pelvic RT in patients with poor prognosis locally advanced rectal cancer (LARC). J. Clin. Oncol. 25: 14500.Google Scholar
  2. Berends, F.J., Kazemier, G., Bonjer, H.J., and Lange, J.F. 1994. Subcutaneous metastasis after laparoscopic colectomy. Lancet 344: 58.PubMedCrossRefGoogle Scholar
  3. Berger, B.M., Vucson, B.M., and Diteberg, J.S. 2003. Gene mutations in advanced colonic polyps: potential worker selection for stool-based mutated human DNA assays for colon cancer screening. Clin. Colorect. Cancer 3: 180–185.CrossRefGoogle Scholar
  4. Bodmer, W.F., Bailey, C.J., Bodmer, J., Bussey, H.J., Ellis, A., Gorman, P., Lucibello, F.C., Murday, A.V., Rider, S.H., Scambler, P., Solomon, S.E., and Spurr, N.K. 1987. Localization of the gene for familial adenomatous polyposis and chromosome 5. Nature 328: 614–616.PubMedCrossRefGoogle Scholar
  5. de Boer, J.G. 2002. Polymorphisms in DNA repair and environmental interactions. Mutat. Res. 509: 201–210.PubMedGoogle Scholar
  6. Booth, R.A. 2007. Minimally invasive biomarkers for detection and staging of colorectal cancer. Cancer Lett. 249: 87–96.PubMedCrossRefGoogle Scholar
  7. Bronner, C.E., Baker, S.M., Morrison, P.T., Warren, G., Smith, L.G., Lescoe, M.K., Kane, M., Earabino, C., Lipford, J., Lindblom, A., Tannergard, P., Bollag, R.J., Godwin, A.R., Ward, D.C., Nordenskjold, M., Fishel, R., Kolodner, R., Liskay, R.M. 1994. Mutation in the DNA mismatch repair gene homologue hMLHI is associated with hereditary nonpolyposis colon cancer. Nature 368: 258–261.PubMedCrossRefGoogle Scholar
  8. Coussens, L.M., and Werb, Z. 2002. Inflammation and Cancer. Nature 420: 860–867.PubMedCrossRefGoogle Scholar
  9. Douillard, J.Y., Cunningham, D., and Roth, A.D. 2000. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multi-center radomised trial. Lancet 355: 1041–1047.PubMedCrossRefGoogle Scholar
  10. Giantonio, B.J., Catalano, P.J., Meropol, N.J., O'Dwyer, P.J., Mitchell, E.P., Alberts, S.R., Schwartz, M.A., and Benson III, A.B. 2007. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 25: 1539–1544.PubMedCrossRefGoogle Scholar
  11. Goldberg, R.M., Sargent, D.J., Morton, R.F., Fuchs, C.S., Ramanathan, R.K., Williamson, S.K., Findlay, B.P., Pitot, H.C., and Alberts, S. 2006. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irino-tecan or infused fluorouracil plus oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J. Clin. Oncol. 24: 3347–3352.PubMedCrossRefGoogle Scholar
  12. Imperiali, G., Minoli, G., Meucci, G.M., Spinzl, G., Strocchi, E., Terruzzi, V., and Radaelli, F. 2007. Effectiveness of a continuous quality improvement program on colonoscopy practice. Endoscopy 39: 314–318.PubMedCrossRefGoogle Scholar
  13. Imperiale, T.F., Ransohoff, D.F., Itzkowitz, S.H., Turnbell, B.A., Ross, M.E., and Colorectal Cancer Study Group. 2004. Fecal DNA versus fecal occult blood for colorectal cancer screening in an average-risk population. N. Engl. J. Med. 351: 2704–2714.PubMedCrossRefGoogle Scholar
  14. Issa, J.P., Shen, L., and Toyota, M. 2005. CIMP, at last. Gastroenterology 129: 1121–1124.PubMedCrossRefGoogle Scholar
  15. Jackson, T.D., Kaplan, G.G., Arena, G., Page, J.H., and Regers, Jr., S.O. 2007. Laparoscopic versus open resection for colorectal cancer: a meta-annalysis of oncologic outcomes. J. Am. Coll. Surg. 204: 439–446.PubMedCrossRefGoogle Scholar
  16. Jeroen, C., Reitsma, J.B., Stoker, J., Bossuyt, P.M., van Deventer, S.J., and Dehker, E. 2006. Polypmissrate determined by tandem colonoscopy: a systematic review. Am. J. Gastroenterol. 101: 343–350.CrossRefGoogle Scholar
  17. Johnson, K.T., Carston, M.J., Wentz, R.J., Manduca, A., Anderson, S.M., and Johnson, C.D. 2007. Development of cathartic-free colorectal cancer screening. Test using virtual colonoscopy: a feasibility study. Am. J. Radiol. 188: W29–W36.Google Scholar
  18. Loktionov, A. 2007. Cell exfoliation in the human colon: myth, reality and implications for color-ectal cancer screenings. Int. J. Cancer 120: 2281–2289.PubMedCrossRefGoogle Scholar
  19. Minami, S., Furui, J., and Kanematsu, T. 2001. Role of carcinoembryonic antigen in the progression of colon cancer cells that express carbohydrate antigen. Cancer Res. 61: 2732–2735.PubMedGoogle Scholar
  20. Nakayama, G., Hibi, K., Nakayama, H., Kodera, Y., Ito, K., Akiyama, S., and Nakao, A. 2007. A highly sensitive method for the detection of p16 methylation in the serum of colorectal cancer patients. Anticancer Res. 27: 1459–1464.PubMedGoogle Scholar
  21. Pawlik, T.M., Scoggins, C.R., Zorzi, D., Abdalla, E.K., Andres, A., Eng, C., Curley, S.A., Loyer, E., Muratore, A., Mentha, G., Caoussotti, L., and Vauthey, J.N. 2005. Effects of surgical margin status on survival and site recurrence after hepatic resection for colorectal metastases. Ann. Surg. 241: 715–722.PubMedCrossRefGoogle Scholar
  22. Ren, J., Xiao, Y.J., Singh, L.S., Zhao, X., Zhao, Z., Feng, L., Rose, T.M., Prestwich, G.D., and Xu, Y. 2006. Lysophosphatidic acid is continually produced by human peritoneal mesothelial cells and enhances adhesion, migration and invasion of ovaria cancer cells. Cancer Res. 66: 3006–3014.PubMedCrossRefGoogle Scholar
  23. Rockey, D.C., Paulson, E., Niedzwiechi, D., Davis, W., Bosworth, H.B., Sanders, L., Yee, J., Henderson, J., Haften, P., Burdich, S., Sanyal, A., Rubin, D.T., Sterlin, M., Aberkar, G., Bhutani, M.S., Binmoeller, K., Garvie, J., Bini, E.J., McQuaid, K., Foster, W.L., Thompson, W.M., Dachman, A., and Halvorsen, R. 2005. Analysis of air contrast barium enema, computed tomo-graphic colonography and colonoscopy: prospective comparison. Lancet 365: 305–311.PubMedGoogle Scholar
  24. Simiantonaki, N., Kurzik-Dumke, U., Karyofylli, G., Tayasinghe, C., Michel-Schmidt, R., and Kirkpatrick, C.J. 2007. Reduced expression of TLR4 is associated with the metastatic status of human colorectal cancer. Inter. J. Mol. Med. 20: 21–29.Google Scholar
  25. Wilson, J., and Balkwill, F. 2002. The role of cytokines in the epithelial cancer microenviron-ment. Semin. Cancer Biol. 12: 113–120.PubMedCrossRefGoogle Scholar
  26. Yeh, C.C., Sung, F.C., Tang, R., Chung-Rong, C.C. and Hsieh, L.L. 2007. Association between polymorphisms of biotransformation and DNA-repair genes and risk of colorectal cancer in Taiwan. J. Biomed. Sci. 14: 183–193.PubMedCrossRefGoogle Scholar
  27. Zhao, Z., Xiao, Y., Elson, P., Tan, H., Plummer, S.J., Berk, M., Aung, P.U.,Lavery, I.C., Achbar, J.P., Li, L., Casey, G., and Xu, Y. 2007. Plasma lysophosphatidylcholine levels: potential biomarkers for colorectal cancer. J. Clin. Onc. 25: 2696–2701.CrossRefGoogle Scholar
  28. Zorzi, D., Laurent, A., Pawlik, T.M., Lauwers, G.Y., Vauthey, J.N., and Abdalla, E.K. 2007. Chemotherapy associated hepatotoxicity and surgery for colorectal liver metastases. Brit. J. Surg. 94: 274–286.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media B.V. 2009

Authors and Affiliations

  • M. A. Hayat

    There are no affiliations available

    Personalised recommendations